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Types of nanoreactors 
Polymers 
They represent the most heterogeneous 
group. The encapsulation can take place 
via the simplest method (physisorption) 
and the enzyme usually can remain 
inside because of electrostatic 
interactions.  
Enzymosomes 
Based on lipids. They have amphipathic 
character and high degree of 
biocompatibility. The most studied are 
liposomes even though they are not the 
most used in enzyme delivery.  
Metallic Inorganic Nanoparticles 
They have an extensive range of 
characteristics suitable for vectorization: 
rich functionality, optical and magnetic 
properties (useful in diagnostic). Among 
them, gold nanoparticles (AuNPs) are 
the most common ones.  
Mesoporous silica nanoparticles 
They are promising candidates due to 
their unique properties, such as easy 
control of the pores diameter during the 
synthesis, high load capacity and their 
robustness. Furthermore, they show low 
cytotoxicity and are biodegradables.   
In the past years, nanomedicine has become an important tool to develop new and also 
more efficient cancer diagnostics and therapies. Selecting the precise cell targets and the 
appropriate nanocarriers is the principal aim of projects in nanomedicine. 
 
Current Cancer Chemotherapies 
The major drawback with current treatments is the prevalence of unrequired dose-limiting 
toxicity to non-cancerous tissues. Moreover, antitumor drugs often show low solubility and 
trend to be deactivated or be degraded in blood circulation.  
Prodrugs and direct enzyme-prodrug therapy (DEPT) 
Drugs precursors do not show cytotoxic activity because they need to be activated by the 
exogenous enzyme. Different targeting strategies as a Antibody-directed, Gene-directed 
and Virus-directed enzyme prodrug therapy have improved the treatments but they have 
also shown some disadvantages: increasing mutation rate, low cell transformation and 
immunoreactivity are some of them.  
This strategy has to use biocompatible nanosystems 
(10-100nm) in order to transport the active enzyme 
to the tumor, where the catalytic reaction will be 
carried out. Low systemic toxicity, effective dose, 
increased enzyme stability and less immonoreativity 
can be  accomplished  with nanoreactors.  
It is required that the nanoreactors show selective 
permeability and low aggregation capacity. 
Tumor Targeting 
Active tumor targeting 
 
Cell proliferation markers: 
Folate receptor, EGFR… 
 
Peptides: Arginine-
Glycine-Aspartic (RGD) 
 
Antibodies 
 
External magnetic fields 
 
Passive tumor targeting 
(Enhance  Permeation 
and Retention) 
 
The tumor vessels have 
increased permeability due 
to aberrant angiogenesis, 
which facilitate the 
accumulation of <200 nm 
nanoreactors. 
NANOREACTORS 
  
Prodrug Active drug 
References 
Some examples 
• Mesoporous silica nanoparticles were 
selected as the material for the D-Amino 
acid oxidase (DAO) delivery system. 
This enzyme catalyze the formation of 
hydrogen peroxide with strong 
oxidability and cytotoxicity. 
The adsorption, activity and stability 
(Figure 1A) of DAO are demonstrated to 
depend mainly on the amino-
functionalization surface.  
Significant cytotoxic effect has been 
observed when the cells are treated by 
the nanoreactor together with D-Alanine 
(Figure 1B).  
Figure 1A. The stability of free 
DAO and DAO encapsulated 
(immobilized or not). 
Figure 1B. Cytotoxic effect 
of the nanoreactor.   
• Studies with ABA triblock copolymer that encapsulate 
Trypanosoma vivax nucleoside hydrolase (TvNH) are 
another experimental approximation to the therapy with 
nanoreactors. This enzyme catalyzes the hydrolysis of 
nucleoside analogues (as some antitumor drugs). To allow 
the entry of the substrate, OmpFor or Tsx, membrane 
proteins, were added. 
The results show that the enzyme activity depends on the 
OmpFor/polymer ratio (Figure 2).  
Figure 2. Product formation rate of 
nanoreactors permeabilized with 
different ratios of membrane protein 
B 
• Another, even more newly experiment used magnetic 
nanoparticles (~30-60 nm) to encapsulate E.Coli cells, 
previously transformed with a vector that overexpressed 
the enzyme cytosine deaminase under the action of a 
temperature inducible promoter.  
The expression of the enzyme induced by magnetic fields 
took place at temperatures of 42-43ºC causing cell death 
but not at physiological conditions (Figure 3). 
 
 
A 
Figure 3. Tumor cell cytotoxicity in 
MCF-7, human breast cancer cell 
after the treatment.  
Conclusions 
Experimental strategy for future in vivo experiments 
Nanotherapy has  brought improvements and efficiency to the current chemotherapy: more 
enzyme stability, low immunoreactivity and less side effects are some examples of what it 
has provided. New approaches based in increasing  the catalytic activity and the 
encapsulating efficiency will let nanotherapy position as the principal strategy for clinic 
studies . 
One can predict that, in the future, we will be able to combine in situ nanoreactors with X-
ray technics to optimise the anticancer treatment.    
 
